
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News / Published News / Clinical Trials</title>
<link>http://www.worldpharmanews.net</link>
<description>World Pharma News .net - Web 2.0 pharmaceutical news portal  votes</description>
<pubDate>Sun, 13 Jul 2008 08:44:53 CEST</pubDate>
<language>en</language>
<item>
<title><![CDATA[Accentia Biopharmaceuticals Inc: Premium Company Profile]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Accentia_Biopharmaceuticals_Inc_Premium_Company_Profile/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Accentia_Biopharmaceuticals_Inc_Premium_Company_Profile/</comments>
<pubDate>Sun, 13 Jul 2008 08:44:53 CEST</pubDate>
<dc:creator>Bharatbook</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Accentia_Biopharmaceuticals_Inc_Premium_Company_Profile/</guid>
<description><![CDATA[Bharatbook.com is proud to announce the new report &quot;Accentia Biopharmaceuticals Inc: Premium Company Profile&quot;from its vast collection of informative market research reports.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novo Nordisk and Neose announce completion of initial phase 1 clinical trial of NN7128]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Novo_Nordisk_and_Neose_announce_completion_of_initial_phase_1_clinical_trial_of_NN7128/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Novo_Nordisk_and_Neose_announce_completion_of_initial_phase_1_clinical_trial_of_NN7128/</comments>
<pubDate>Wed, 04 Jun 2008 00:14:19 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Novo_Nordisk_and_Neose_announce_completion_of_initial_phase_1_clinical_trial_of_NN7128/</guid>
<description><![CDATA[Novo Nordisk A/S (NYSE:NVO) and Neose Technologies, Inc. (Nasdaq GM: NTEC) announced that Novo Nordisk has completed the initial phase 1 clinical trial with NN7128 (GlycoPEGylated factor VIIa), a lon<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Phase_III_Study_of_Abbotts_Investigational_TriLipixTM_in_Combination_With_AstraZenecas_CRESTORR/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Phase_III_Study_of_Abbotts_Investigational_TriLipixTM_in_Combination_With_AstraZenecas_CRESTORR/</comments>
<pubDate>Tue, 03 Jun 2008 00:05:32 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Phase_III_Study_of_Abbotts_Investigational_TriLipixTM_in_Combination_With_AstraZenecas_CRESTORR/</guid>
<description><![CDATA[New Phase III data showed that in patients with multiple lipid problems, Abbott's investigational TriLipix(TM) (ABT-335) combined with AstraZeneca's CRESTOR(R) (rosuvastatin calcium) led to greater<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lapatinib (Tykerb/Tyverb) to be investigated in landmark early breast cancer trial]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Lapatinib_TykerbTyverb_to_be_investigated_in_landmark_early_breast_cancer_trial/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Lapatinib_TykerbTyverb_to_be_investigated_in_landmark_early_breast_cancer_trial/</comments>
<pubDate>Thu, 15 May 2008 03:04:30 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Lapatinib_TykerbTyverb_to_be_investigated_in_landmark_early_breast_cancer_trial/</guid>
<description><![CDATA[GlaxoSmithKline (GSK), in collaboration with the Breast International Group (BIG), a leading academic breast cancer research network, and one of its member groups, the Spanish Breast Cancer Cooperati<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Boehringer Ingelheim announces commitment to progressing science with the Bouquet Studies]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Boehringer_Ingelheim_announces_commitment_to_progressing_science_with_the_Bouquet_Studies/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Boehringer_Ingelheim_announces_commitment_to_progressing_science_with_the_Bouquet_Studies/</comments>
<pubDate>Tue, 13 May 2008 00:49:19 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Boehringer_Ingelheim_announces_commitment_to_progressing_science_with_the_Bouquet_Studies/</guid>
<description><![CDATA[Data announced at the American College of Obstetricians and Gynaecologists (ACOG) annual clinical meeting suggest that up to one in ten women are suffering from a condition called hypoactive sexual d<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[International study to evaluate efficacy and safety in treating a leading cause of blindness]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/International_study_to_evaluate_efficacy_and_safety_in_treating_a_leading_cause_of_blindness/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/International_study_to_evaluate_efficacy_and_safety_in_treating_a_leading_cause_of_blindness/</comments>
<pubDate>Sat, 10 May 2008 00:09:00 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/International_study_to_evaluate_efficacy_and_safety_in_treating_a_leading_cause_of_blindness/</guid>
<description><![CDATA[Bayer HealthCare AG and development partner Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Highlight Potential of Novel Oral Compound for Gaucher Disease]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Highlight_Potential_of_Novel_Oral_Compound_for_Gaucher_Disease/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Highlight_Potential_of_Novel_Oral_Compound_for_Gaucher_Disease/</comments>
<pubDate>Fri, 09 May 2008 00:31:11 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Highlight_Potential_of_Novel_Oral_Compound_for_Gaucher_Disease/</guid>
<description><![CDATA[Genzyme Corp. (NASDAQ: GENZ) reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compo<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Results from phase 2b &quot;DEEP&quot; study in severe pre-eclampsia]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Results_from_phase_2b_DEEP_study_in_severe_pre-eclampsia/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Results_from_phase_2b_DEEP_study_in_severe_pre-eclampsia/</comments>
<pubDate>Wed, 23 Apr 2008 23:10:06 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Results_from_phase_2b_DEEP_study_in_severe_pre-eclampsia/</guid>
<description><![CDATA[Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announces that its placebo-controlled phase 2b Digoxin Immune Fab (DIF) Efficacy Evaluation in P<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FTY720, a novel oral therapy in development for multiple sclerosis]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/FTY720_a_novel_oral_therapy_in_development_for_multiple_sclerosis/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/FTY720_a_novel_oral_therapy_in_development_for_multiple_sclerosis/</comments>
<pubDate>Tue, 22 Apr 2008 00:10:41 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/FTY720_a_novel_oral_therapy_in_development_for_multiple_sclerosis/</guid>
<description><![CDATA[The investigational oral therapy FTY720 (fingolimod) continues to demonstrate sustained benefits in patients with multiple sclerosis (MS) after three years of treatment, according to new clinical dat<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Princess Zetia and the pea]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Princess_Zetia_and_the_pea/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Princess_Zetia_and_the_pea/</comments>
<pubDate>Thu, 10 Apr 2008 07:33:31 CEST</pubDate>
<dc:creator>SMB</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Princess_Zetia_and_the_pea/</guid>
<description><![CDATA[Newly reported Zetia non-study<br/><br/>4 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Crestor Outcomes Study JUPITER Closes Early Due To Unequivocal Evidence Of Benefit]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Crestor_Outcomes_Study_JUPITER_Closes_Early_Due_To_Unequivocal_Evidence_Of_Benefit/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Crestor_Outcomes_Study_JUPITER_Closes_Early_Due_To_Unequivocal_Evidence_Of_Benefit/</comments>
<pubDate>Tue, 01 Apr 2008 00:05:04 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Crestor_Outcomes_Study_JUPITER_Closes_Early_Due_To_Unequivocal_Evidence_Of_Benefit/</guid>
<description><![CDATA[AstraZeneca today announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, whi<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Door Knobs As Antibacterials?]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Door_Knobs_As_Antibacterials-1/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Door_Knobs_As_Antibacterials-1/</comments>
<pubDate>Fri, 28 Mar 2008 00:18:31 CET</pubDate>
<dc:creator>cliffmz</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Door_Knobs_As_Antibacterials-1/</guid>
<description><![CDATA[Metals like copper and silver have long been known to possess antibacterial properties. I learned this as an undergraduate microbiology major circa 1972. That said, I didn't know whether to laugh or <br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/First_Clinical_Trial_of_a_Fully_Bioabsorbable_Drug_Eluting_Coronary_Stent/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/First_Clinical_Trial_of_a_Fully_Bioabsorbable_Drug_Eluting_Coronary_Stent/</comments>
<pubDate>Sat, 15 Mar 2008 00:12:31 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/First_Clinical_Trial_of_a_Fully_Bioabsorbable_Drug_Eluting_Coronary_Stent/</guid>
<description><![CDATA[Data published in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis,<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[A Day of Shame for Science in the United Kingdom]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/A_Day_of_Shame_for_Science_in_the_United_Kingdom-1/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/A_Day_of_Shame_for_Science_in_the_United_Kingdom-1/</comments>
<pubDate>Fri, 07 Mar 2008 14:31:58 CET</pubDate>
<dc:creator>SMB</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/A_Day_of_Shame_for_Science_in_the_United_Kingdom-1/</guid>
<description><![CDATA[Paxil/Seroxat Scientific Misconduct<br/><br/>4 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Update on GSK's malaria treatments: Dacart and Lapdap]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Update_on_GSKs_malaria_treatments_Dacart_and_Lapdap/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Update_on_GSKs_malaria_treatments_Dacart_and_Lapdap/</comments>
<pubDate>Tue, 04 Mar 2008 00:19:32 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Update_on_GSKs_malaria_treatments_Dacart_and_Lapdap/</guid>
<description><![CDATA[Malaria is a devastating disease killing over one million people, mostly young children and pregnant women every year. There is an urgent need for new medicines to treat the disease as resistance bui<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca Provides Update On RECENTIN Clinical Development Programme]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/AstraZeneca_Provides_Update_On_RECENTIN%C2%99_Clinical_Development_Programme/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/AstraZeneca_Provides_Update_On_RECENTIN%C2%99_Clinical_Development_Programme/</comments>
<pubDate>Thu, 28 Feb 2008 00:35:48 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/AstraZeneca_Provides_Update_On_RECENTIN%C2%99_Clinical_Development_Programme/</guid>
<description><![CDATA[AstraZeneca today announced that its HORIZON III Phase II/III head-to-head study of RECENTIN™ (cediranib, AZD2171) with chemotherapy versus bevacizumab (Avastin™) with chemotherapy in patients with f<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer and Onyx Provide Update on Phase III Trial of Nexavar]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Bayer_and_Onyx_Provide_Update_on_Phase_III_Trial_of_Nexavar%AE/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Bayer_and_Onyx_Provide_Update_on_Phase_III_Trial_of_Nexavar%AE/</comments>
<pubDate>Wed, 20 Feb 2008 00:07:34 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Bayer_and_Onyx_Provide_Update_on_Phase_III_Trial_of_Nexavar%AE/</guid>
<description><![CDATA[Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. announced that a Phase III trial evaluating Nexavar® (sorafenib) tablets in patients with non-small cell lung cancer (NSCLC) was stoppe<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA grants fast track designation for Boehringer Ingelheim's BIBW 2992]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/FDA_grants_fast_track_designation_for_Boehringer_Ingelheims_BIBW_2992/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/FDA_grants_fast_track_designation_for_Boehringer_Ingelheims_BIBW_2992/</comments>
<pubDate>Mon, 18 Feb 2008 11:24:59 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/FDA_grants_fast_track_designation_for_Boehringer_Ingelheims_BIBW_2992/</guid>
<description><![CDATA[Boehringer Ingelheim's investigational cancer treatment BIBW 2992 has recently received a Fast Track Designation status by the FDA. Under this designation, Boehringer Ingelheim will conduct a pivota<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Suicide warning over clinical trials - New Scientist (subscription)]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Suicide_warning_over_clinical_trials_-_New_Scientist_subscription/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Suicide_warning_over_clinical_trials_-_New_Scientist_subscription/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:55 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Suicide_warning_over_clinical_trials_-_New_Scientist_subscription/</guid>
<description><![CDATA[Suicide warning over clinical trialsNew Scientist (subscription),&amp;nbsp;UK&amp;nbsp;- 1 hour agoDrug companies are being asked to pay special attention to<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Clinical Trials Update: Jan. 30, 2008 - U.S. News &amp; World Report]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Clinical_Trials_Update_Jan-_30_2008_-_U-S-_News__World_Report/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Clinical_Trials_Update_Jan-_30_2008_-_U-S-_News__World_Report/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:55 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Clinical_Trials_Update_Jan-_30_2008_-_U-S-_News__World_Report/</guid>
<description><![CDATA[Clinical Trials Update: Jan. 30, 2008U.S. News &amp; World Report,&amp;nbsp;DC&amp;nbsp;- 2 hours agoIf you have osteoarthritis of the knee, you may qualify for <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Stem Cell Therapy Studies For Stroke, Cerebral Palsy Prepare For ... - Science Daily (press release)]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Stem_Cell_Therapy_Studies_For_Stroke_Cerebral_Palsy_Prepare_For_---_-_Science_Daily_press_release/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Stem_Cell_Therapy_Studies_For_Stroke_Cerebral_Palsy_Prepare_For_---_-_Science_Daily_press_release/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:55 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Stem_Cell_Therapy_Studies_For_Stroke_Cerebral_Palsy_Prepare_For_---_-_Science_Daily_press_release/</guid>
<description><![CDATA[Stem Cell Therapy Studies For Stroke, Cerebral Palsy Prepare For ...Science Daily (press release)&amp;nbsp;- 19 hours agoThe answers are critical before <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical ... - CNNMoney.com]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Peregrine_Pharmaceuticals_Opens_Enrollment_in_Phase_II_Clinical_---_-_CNNMoney-com/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Peregrine_Pharmaceuticals_Opens_Enrollment_in_Phase_II_Clinical_---_-_CNNMoney-com/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:55 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Peregrine_Pharmaceuticals_Opens_Enrollment_in_Phase_II_Clinical_---_-_CNNMoney-com/</guid>
<description><![CDATA[Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical ...CNNMoney.com&amp;nbsp;- Jan 29, 2008Bavituximab is in clinical trials in the US in pat<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Clinical Trials Update: Jan. 29, 2008 - U.S. News &amp; World Report]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Clinical_Trials_Update_Jan-_29_2008_-_U-S-_News__World_Report/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Clinical_Trials_Update_Jan-_29_2008_-_U-S-_News__World_Report/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:55 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Clinical_Trials_Update_Jan-_29_2008_-_U-S-_News__World_Report/</guid>
<description><![CDATA[Clinical Trials Update: Jan. 29, 2008U.S. News &amp; World Report,&amp;nbsp;DC&amp;nbsp;- Jan 29, 2008If you are 18 or older, female, African American, and have <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[OncoMethylome Sciences SA To Initiate A Large Colorectal Cancer ... - ABN Newswire (press release)]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/OncoMethylome_Sciences_SA_To_Initiate_A_Large_Colorectal_Cancer_---_-_ABN_Newswire_press_release/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/OncoMethylome_Sciences_SA_To_Initiate_A_Large_Colorectal_Cancer_---_-_ABN_Newswire_press_release/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:55 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/OncoMethylome_Sciences_SA_To_Initiate_A_Large_Colorectal_Cancer_---_-_ABN_Newswire_press_release/</guid>
<description><![CDATA[OncoMethylome Sciences SA To Initiate A Large Colorectal Cancer ...ABN Newswire (press release),&amp;nbsp;Australia&amp;nbsp;- 12 hours agoSignature Diagnost<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New lease on life? The ethics of offshoring clinical trials - Financial Times (subscription)]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/New_lease_on_life_The_ethics_of_offshoring_clinical_trials_-_Financial_Times_subscription/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/New_lease_on_life_The_ethics_of_offshoring_clinical_trials_-_Financial_Times_subscription/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:55 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/New_lease_on_life_The_ethics_of_offshoring_clinical_trials_-_Financial_Times_subscription/</guid>
<description><![CDATA[New lease on life? The ethics of offshoring clinical trialsFinancial Times (subscription),&amp;nbsp;UK&amp;nbsp;- Jan 28, 2008Even so, such practices highlig<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Nuvelo_Initiates_Phase_1_Clinical_Trial_of_Thrombin_Inhibitor_NU172-2/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Nuvelo_Initiates_Phase_1_Clinical_Trial_of_Thrombin_Inhibitor_NU172-2/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Nuvelo_Initiates_Phase_1_Clinical_Trial_of_Thrombin_Inhibitor_NU172-2/</guid>
<description><![CDATA[Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172CNNMoney.com&amp;nbsp;- Jan 30, 2008... without limitation, uncertainties relating to<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/AVEO_Initiates_Phase_1b_Combination_Clinical_Trial_of_Novel_Triple_VEGF_Receptor_Inhibitor/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/AVEO_Initiates_Phase_1b_Combination_Clinical_Trial_of_Novel_Triple_VEGF_Receptor_Inhibitor/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/AVEO_Initiates_Phase_1b_Combination_Clinical_Trial_of_Novel_Triple_VEGF_Receptor_Inhibitor/</guid>
<description><![CDATA[AVEO Initiates Phase 1b  Combination Clinical Trial of Novel Triple ...Business Wire (press release),&amp;nbsp;CA&amp;nbsp;- Jan 31, 2008For more information<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[When Drug Trials Go Wrong, Patients Have Little Recourse]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/When_Drug_Trials_Go_Wrong_Patients_Have_Little_Recourse/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/When_Drug_Trials_Go_Wrong_Patients_Have_Little_Recourse/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/When_Drug_Trials_Go_Wrong_Patients_Have_Little_Recourse/</guid>
<description><![CDATA[When Drug Trials Go Wrong, Patients Have Little RecourseWall Street Journal&amp;nbsp;- Jan 30, 2008The case highlights one aspect of the legal and regula<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[ReNeuron announces a date with FDA over stroke therapy trials]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/ReNeuron_announces_a_date_with_FDA_over_stroke_therapy_trials-1/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/ReNeuron_announces_a_date_with_FDA_over_stroke_therapy_trials-1/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/ReNeuron_announces_a_date_with_FDA_over_stroke_therapy_trials-1/</guid>
<description><![CDATA[Enews 2.0ReNeuron announces a date with FDA over stroke therapy trialsHemscott,&amp;nbsp;UK&amp;nbsp;- 7 hours agoIn September last year ReNeuron announced t<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Cytokinetics, Incorporated Reports Fourth Quarter and Year End ... - CNNMoney.com]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Cytokinetics_Incorporated_Reports_Fourth_Quarter_and_Year_End_---_-_CNNMoney-com/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Cytokinetics_Incorporated_Reports_Fourth_Quarter_and_Year_End_---_-_CNNMoney-com/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Cytokinetics_Incorporated_Reports_Fourth_Quarter_and_Year_End_---_-_CNNMoney-com/</guid>
<description><![CDATA[Cytokinetics, Incorporated Reports Fourth Quarter and Year End ...CNNMoney.com&amp;nbsp;- 17 hours agoIn particular, we progressed and expanded the  clin<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Amicus Therapeutics to Present at the Merrill Lynch Global ... - CNNMoney.com]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Amicus_Therapeutics_to_Present_at_the_Merrill_Lynch_Global_---_-_CNNMoney-com/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Amicus_Therapeutics_to_Present_at_the_Merrill_Lynch_Global_---_-_CNNMoney-com/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Amicus_Therapeutics_to_Present_at_the_Merrill_Lynch_Global_---_-_CNNMoney-com/</guid>
<description><![CDATA[Amicus Therapeutics to Present at the Merrill Lynch Global ...CNNMoney.com&amp;nbsp;- 1 hour agoAmicus has completed Phase 2 clinical trials of Amigal fo<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/DATATRAKTM_Takes_Clinical_Trial_Solutions_to_the_Next_Level_With_the_Release_of_5-0/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/DATATRAKTM_Takes_Clinical_Trial_Solutions_to_the_Next_Level_With_the_Release_of_5-0/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/DATATRAKTM_Takes_Clinical_Trial_Solutions_to_the_Next_Level_With_the_Release_of_5-0/</guid>
<description><![CDATA[DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With ...CNNMoney.com&amp;nbsp;- Jan 30, 200830 /PRNewswire-FirstCall/ -- DATATRAK Internati<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Analytical Results for Women from Large Scale Clinical Trial MEGA Study]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Analytical_Results_for_Women_from_Large_Scale_Clinical_Trial_MEGA_Study/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Analytical_Results_for_Women_from_Large_Scale_Clinical_Trial_MEGA_Study/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Analytical_Results_for_Women_from_Large_Scale_Clinical_Trial_MEGA_Study/</guid>
<description><![CDATA[Analytical Results for Women from Large Scale Clinical Trial MEGA ...PharmaLive.com (press release),&amp;nbsp;PA&amp;nbsp;- 33 minutes ago... emeritus profes<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/MediciNovas_MN-166_Reduces_Persistent_Black_Hole_Formation_in_Multiple_Sclerosis_Patients/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/MediciNovas_MN-166_Reduces_Persistent_Black_Hole_Formation_in_Multiple_Sclerosis_Patients/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/MediciNovas_MN-166_Reduces_Persistent_Black_Hole_Formation_in_Multiple_Sclerosis_Patients/</guid>
<description><![CDATA[MediciNova&amp;#39;s MN-166 Reduces Persistent Black Hole Formation in ...CNNMoney.com&amp;nbsp;- 5 hours agoThese forward-looking statements include, withou<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New Initiative Trains Nurses to Manage Clinical Trials]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/New_Initiative_Trains_Nurses_to_Manage_Clinical_Trials-1/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/New_Initiative_Trains_Nurses_to_Manage_Clinical_Trials-1/</comments>
<pubDate>Thu, 31 Jan 2008 22:05:06 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/New_Initiative_Trains_Nurses_to_Manage_Clinical_Trials-1/</guid>
<description><![CDATA[New Initiative Trains Nurses to Manage Clinical TrialsMedia Newswire (press release),&amp;nbsp;NY&amp;nbsp;- 2 hours agoA critical step in moving medical adv<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Nuvelo_Initiates_Phase_1_Clinical_Trial_of_Thrombin_Inhibitor_NU172-1/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Nuvelo_Initiates_Phase_1_Clinical_Trial_of_Thrombin_Inhibitor_NU172-1/</comments>
<pubDate>Thu, 31 Jan 2008 21:55:32 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Nuvelo_Initiates_Phase_1_Clinical_Trial_of_Thrombin_Inhibitor_NU172-1/</guid>
<description><![CDATA[Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172CNNMoney.com&amp;nbsp;- 5 hours ago... without limitation, uncertainties relating to<br/><br/>2 Vote(s) ]]></description>
</item>

</channel>
</rss>
